GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (FRA:04I) » Definitions » Price-to-Owner-Earnings

InVivo Therapeutics Holdings (FRA:04I) Price-to-Owner-Earnings : (As of Jun. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is InVivo Therapeutics Holdings Price-to-Owner-Earnings?

As of today (2024-06-14), InVivo Therapeutics Holdings's share price is €0.2545. InVivo Therapeutics Holdings does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for InVivo Therapeutics Holdings's Price-to-Owner-Earnings or its related term are showing as below:


FRA:04I's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.65
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-14), InVivo Therapeutics Holdings's share price is €0.2545. InVivo Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was €-3.08. Therefore, InVivo Therapeutics Holdings's PE Ratio for today is At Loss.

As of today (2024-06-14), InVivo Therapeutics Holdings's share price is €0.2545. InVivo Therapeutics Holdings's EPS without NRI for the trailing twelve months (TTM) ended in was €-3.08. Therefore, InVivo Therapeutics Holdings's PE Ratio without NRI for today is At Loss.


InVivo Therapeutics Holdings Price-to-Owner-Earnings Historical Data

The historical data trend for InVivo Therapeutics Holdings's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InVivo Therapeutics Holdings Price-to-Owner-Earnings Chart

InVivo Therapeutics Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

InVivo Therapeutics Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of InVivo Therapeutics Holdings's Price-to-Owner-Earnings

For the Biotechnology subindustry, InVivo Therapeutics Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InVivo Therapeutics Holdings's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where InVivo Therapeutics Holdings's Price-to-Owner-Earnings falls into.



InVivo Therapeutics Holdings Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

InVivo Therapeutics Holdings's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.2545/-2.19
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InVivo Therapeutics Holdings  (FRA:04I) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


InVivo Therapeutics Holdings Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


InVivo Therapeutics Holdings (FRA:04I) Business Description

Traded in Other Exchanges
Address
One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139
InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.

InVivo Therapeutics Holdings (FRA:04I) Headlines

No Headlines